학술논문

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Document Type
Article
Source
In Annals of Oncology November 2019 30(11):1821-1830
Subject
Language
ISSN
0923-7534